Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of ...

Albumin industry is projected to witness a CAGR of 6.5% during the period 2024-2032. This growth can be attributed to ...

On Wednesday, Sonnet’s stock saw a dramatic rise, making it one of the most talked-about biotech stocks of the day. This uptick comes in the wake of a key announcement from the company: the issuance ...

Sonnet BioTherapeutics Holdings, Inc. disclosed in an 8-K filing with the SEC on November 6, 2024, that it has successfully completed an underwritten public offering aimed at raising $5.0 million in ...

Creatinine is measured via a smartphone-based imaging system, while albumin levels are assessed with an indigenously ...

The A/G ratio describes the amount of albumin compared to the amount of globulin in your blood. Both are called serum proteins. They have different purposes in the human body, as follows: Under normal ...

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or ...

The antibody targeting ROR1, CD3, and human serum albumin, is the firm's first cancer drug to enter clinical trials.

IL-18 plays a key role in regulating innate immune responses, affecting natural killer cells, monocytes and other cell types.